Search
- Jan 22
Roivant's Matt Gline on the success of Telavant, Immunovant's FcRn program, and his expectations for the company's cash usage
Matt Gline reflects on learnings from the Telavant success, and why he thinks Immunovant's FcRn might be best in class.